Search Results for “antibody” – Page 3 – media

The Lancet sub-journal publishes clinical phase 1b/2 results of the next-generation CD20 antibody MIL62 in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma and marginal zone lymphoma

Recently, eClinical Medicine, a sub-journal of The Lancet, published the results of a phase 1b/2 study of recombinant humanized monoclonal antibody MIL62 injection in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma and marginal zone lymphoma, led by Prof. Yuankai Shi of Cancer Hospital, Chinese Academy of Medical Sciences. The study was designed to evaluate the efficacy and safety of MIL62 in combination with lenalidomide in the treatment of relapsed/refractory follicular lymphoma and marginal zone lymphoma. Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are common pathological subtypes of non-Hodgkin’s lymphoma (NHL) and are inert lymphomas. In China, FL accounts for about 8% of B-cell NHL, while MZL accounts for about 12%. Early progression in patients with inert lymphoma is directly related to poor prognosis, with approximately 20% of patients experiencing disease recurrence or progression within 24 months of diagnosis (POD24). These patients typically have a poor prognosis, ...
- Source: drugdu
- 105
- June 29, 2024
Leads Biolabs’ Innovative Cancer Treatment LBL-024, an Anti-PDL1/4-1BB Bispecific Antibody Achieved Outstanding Phase II Results, Has Been Presented in Clinical Science Symposium at 2024 ASCO Annual Meeting.

NANJING, China, June 3, 2024 /PRNewswire/ — The annual meeting of the American Society of Clinical Oncology (ASCO) commenced on May 31st, Showcasing groundbreaking cancer research from around the world. According to official information, over 7,000 abstracts were submitted this year. After rigorous evaluation by Scientific Program Committee and ASCO Leadership, LBL-024, a bispecific antibody independently developed by Leads Biolabs with global intellectual property rights, was selected for an oral presentation. Today, Dr. Panpan Zhang, the investigator of LBL-024, presented the outstanding clinical data during the Clinical Science Symposium-Building Novel Antibody-Based Approaches in Gastrointestinal Cancers. This is a phase I/II first in human, open-label, multicenter, dose escalation/expansion study that evaluates the safety and efficacy of LBL-024 monotherapy in patients with advanced malignant tumors and neuroendocrine carcinoma. The study results demonstrated good safety profile and very promising antitumor effects as a monotherapy in patients with advanced malignant tumors, particularly extrapulmonary neuroendocrine ...
- Source: drugdu
- 139
- June 4, 2024
J&J Adds Another Bispecific Antibody for Atopic Dermatitis With $1.25B Acquisition

Johnson & Johnson is acquiring a bispecific antibody that Numab Therapeutics engineered to address two pathways associated with the inflammation and itching of atopic dermatitis. It’s J&J’s second immunology acquisition this month. By Frank Vinluan Johnson & Johnson is building up its immunology pipeline, striking a $1.25 billion deal for a bispecific antibody in development for atopic dermatitis — its second acquisition agreement in the indication in the past two weeks. The deal announced Tuesday will bring J&J a Numab Therapeutics drug codenamed NM26. The pharmaceutical giant is acquiring global rights to the experimental treatment, which is ready to enter Phase 2 testing. Atopic dermatitis, also known as eczema, is the most common inflammatory skin disease. While the disorder typically presents as red and itchy skin, it stems from multiple pathways that vary from one group of patients to another. NM26 is a bispecific antibody designed to address two of ...
- Source: drugdu
- 107
- May 31, 2024
Johnson & Johnson Acquires Numab’s Investigational Antibody for the Treatment of Atopic Dermatitis

Don Tracy, Associate Editor The acquisition of a novel therapy for atopic dermatitis includes an all-cash transaction totaling approximately $1.25 billion. Image Credit: Adobe Stock Images/Ityuan Johnson & Johnson (J&J) announced that it has agreed to terms with Numab Therapeutics to acquire its wholly owned subsidiary for the global rights to NM26, an investigational bispecific antibody currently in Phase II of development for the treatment of atopic dermatitis (AD). Under terms of the deal, J&J will pay Numab around $1.25 billion in an all-cash transaction. According to the company, the transaction is expected to close later this year, clearance under the Hart-Scott-Rodino Antitrust Improvements Act and fulfillment of customary closing conditions. NM26 targets two established pathways, interleukin (IL)-4Rα and IL-31, in AD. According to investigators, this works by targeting IL-4Rα, which is responsible for Th2-mediated skin inflammation, and IL-31, which triggers skin itch and exacerbates AD. Additionally, NM26 has demonstrated ...
- Source: drugdu
- 77
- May 31, 2024
World’s First One-Minute Hepatitis C Antibody Test Facilitates Quick Triage

Rapid and accurate testing is crucial in the fight against Hepatitis C. Hepatitis C blood testing determines whether someone has been infected with the Hepatitis C virus. Having regular access to testing helps ensure the prompt identification of potential Hepatitis C infections and facilitates immediate linkage to care, thus helping to reduce further transmission. Now, the first one-minute Hepatitis C antibody test can prove to be an excellent tool in managing this disease. The INSTI HCV Antibody Test from bioLytical Laboratories (Richmond, BC, Canada) is the world’s first one-minute test that detects antibodies to the Hepatitis C virus, which are substances released into the bloodstream upon infection. The test includes procedural control for IgG and IgM and can identify HCV genotypes 1 through 6, delivering results in as little as 60 seconds. It is both highly accurate and affordable, designed for ease of use. This fully portable system does not ...
- Source: drugdu
- 77
- May 23, 2024
Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset

Autoimmune diseases such as multiple sclerosis (MS) are thought to occur partly due to unusual immune responses to common infections. Early MS symptoms, including dizziness, spasms, and fatigue, often resemble other conditions, complicating diagnosis, which heavily relies on detailed brain MRI evaluations. MS can severely impair motor control, but advancements in treatment can slow down its progression and help maintain functions such as walking. Notably, around 10% of MS patients begin producing a distinctive set of antibodies against their own proteins years before symptoms appear. These autoantibodies have been found to bind to both human cells and common pathogens, possibly explaining why immune attacks on the brain and spinal cord occur in MS. Now, researchers have identified a unique autoantibody signature in about 10% of MS patients that appears years before the onset of clinical symptoms, raising hopes for early detection via a simple blood test and earlier treatment initiation. ...
- Source: drugdu
- 87
- April 25, 2024
Diagonal Therapeutics’ New Slant Attracts $128M to Reactivate Antibody Drug R&D

Diagonal Therapeutics develops agonist antibodies to treat rare cardiovascular conditions. Using artificial intelligence, the startup’s technology sorts through billions of antibody/receptor combinations to identify the ones that reactivate signaling pathways lost to disease.In a drug discovery career spanning more than two decades, Alex Lugovskoy has seen a lot of antibodies come and go. The vast majority of them work by inhibiting a cellular function. Lugovskoy, now the CEO of startup Diagonal Therapeutics, said he long hoped someone would come up with a way to develop antibodies that activate their targets. With each passing year, no one did. So he took up the challenge himself. Diagonal uses computational and experimental techniques to understand what happens when an antibody binds to a receptor and which binding combinations will yield the desired effect. After developing its platform for the past two years, the startup this past week pulled back the curtain on its ...
- Source: drugdu
- 91
- April 9, 2024
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy

ROCKVILLE, Md. and SUZHOU, China, March 27, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been successfully dosed with IBI310 (anti-CTLA-4 monoclonal antibody) in combination with sintilimab (PD-1 inhibitor) in a randomized, controlled, multicenter Phase 3 clinical trial (Neoshot), for resectable MSI-H/dMMR[1] colon cancer (stage cT4 or cN+) neoadjuvant therapy. Neoshot is the first Phase 3 clinical trial (NCT05890742) in China to investigate MSI-H/dMMR colon cancer neoadjuvant immunotherapy. The study will evaluate the safety and efficacy of IBI310 combined with sintilimab for neoadjuvant therapy, compared with adjuvant chemotherapy after radical surgery for MSI-H/dMMR colon cancer. The primary endpoints are pathologic complete response (pCR) rate and event-free survival (EFS). Previously, in a randomized, controlled, multicenter Phase 1b study for neoadjuvant ...
- Source: drugdu
- 128
- April 1, 2024
The latest data of Akesobio’s “PD-1/VEGF dual antibody” Ivonescimab combined with chemotherapy for first-line treatment of NSCLC are announced

At the high-profile European Lung Cancer Conference (ELCC) 2024, Akesobio and its partner Summit Therapeutics (Summit) jointly released the PD-1/VEGF dual antibody Ivonescimab(AK112/SMT112) combined with chemotherapy for the first-line treatment of advanced non-cancer lung cancer. Updated data from Cohort 1 (EGFR/ALK wild type) of the Phase II small cell lung cancer (NSCLC) clinical study (AK112-201). Previous research results have been published at the 2023 ASCO Annual Meeting and eClinical Medicine, a subsidiary of the top international medical journal “The Lancet”. Cohort 1 included a total of 135 patients with EGFR/ALK wild-type NSCLC who received Ivonescimab combined with chemotherapy, including 63 patients with squamous cell carcinoma and 72 patients with non-squamous cell carcinoma. As of October 2023, the median follow-up time has been further extended to 21.3 months. As the follow-up time is extended, the clinical advantages of Ivosib in the first-line treatment of advanced or metastatic NSCLC become more obvious. ...
- Source: drugdu
- 125
- March 30, 2024
Biotheus Expanded Their Partnership with Hansoh Pharma for Developing EGFR/cMET Bispecific Antibody-Drug Conjugates

ZHUHAI, China, March 15, 2024 /PRNewswire/ — On March 14, 2024, Biotheus Inc. (Biotheus), a clinical-stage biotech company focusing on the discovery and development of biologics for oncology and inflammatory diseases, and Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma,03692.HK), China’s leading innovation-driven pharmaceutical company, jointly announced that the two parties will further expand their strategic collaboration, following their current partnership since 2022. Biotheus will grant Hansoh Pharma a license to use the proprietary anti-EGFR/cMet bispecific antibody PM1080/HS-20117 independently developed by Biotheus for the development of antibody-drug conjugates products (ADC Product). Under the terms of the agreement, Hansoh Pharma will obtain exclusive worldwide rights from Biotheus to use PM1080/HS-20117 for the development, production, and commercialization of ADC Product, with the right of sublicense. Biotheus will be eligible to receive up to 5 billion RMB in upfront and success-based milestones for ADC Product, as well as tiered royalties based on global net ...
- Source: drugdu
- 171
- March 19, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.